跳至主要内容
临床试验/2023-509094-23-00
2023-509094-23-00招募中4 期

A randomized comparison of one controlled ovarian stimulation with corifollitropin alfa (CFA) versus up to three modified natural cycles (MNC) in expected and established poor responders

Universitair Ziekenhuis Gent1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2024年6月27日最近更新:
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
300
试验地点
1
主要终点
the probability of having at least one good quality blastocyst after ART (on the day of embryo transfer) (binary endpoint).

研究概览

简要总结

to compare the probability of having at least one good quality blastocyst after CFA stimulation versus the probability of having at least one good quality blastocyst after a first MNC, in women with a clinical indication for ART and an expected low response to ovarian stimulation. Good quality is defined by the Gardner score 5AA, 5AB or 5BA.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Two Strategies For The Management Of Predicted Low Prognosis Patients Under Stimulation For Ivf/icsi
盲法
None

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • women with a clinical indication for ART with an expected low response to ovarian stimulation. Expected low prognosis will be defined according to the POSEIDON classification, which stratifies patients according to whether they have an unexpected (groups 1 and 2) or expected (groups 3 or 4) inappropriate ovarian response to gonadotropin stimulation. This trial only includes patients fulfilling the criteria of groups 3 or 4: • POSEIDON Group 3: patients < 35 years with poor ovarian reserve pre-stimulation parameters (AFC < 5 or AMH < 1.2 ng/ml*) • POSEIDON Group 4: patients ≥ 35 years with poor ovarian reserve pre-stimulation parameters (AFC < 5 or AMH < 1.2 ng/ml*) * AMH value should not be older than 12 months.
  • Informed consent form (ICF) dated and signed
  • Age ≥ 18 and < 45 years old
  • Body Mass Index (BMI) ≥ 18.5 kg/m² and < 35 kg/m²
  • Regular menstrual cycles (between 21 and 35 days)
  • Two ovaries present
  • Current pregnancy-wish
  • Single embryo transfer (SET)

排除标准

  • Basal FSH > 20 IU/L in the last 12 months
  • Simultaneous participation in another clinical study
  • Untreated and uncontrolled thyroid dysfunction
  • Tumors of the ovary, breast, uterus, pituitary or hypothalamus
  • Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause
  • Malformations of the reproductive organs
  • Current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy
  • Previous antibiotic hypersensitivity reactions (streptomycin and/or neomycin)
  • Patients who undergo preimplantation genetic testing (PGT), fertility preservation or oocyte donation

结局指标

主要结局

the probability of having at least one good quality blastocyst after ART (on the day of embryo transfer) (binary endpoint).

the probability of having at least one good quality blastocyst after ART (on the day of embryo transfer) (binary endpoint).

次要结局

  • the relative number of blastocyts after ART (on the day of embryo transfer), relative to the number of oocytes (rate)
  • the probability of having at least one blastocyst of good quality after ART (on the day of embryo transfer) (binary endpoint)
  • the probability of having an ongoing pregnancy which is defined as 6 to 8 weeks gestational age (binary endpoint) o Related sensitivity endpoint:, as confirmed by ultrasound (time to event)

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Wijnant Kathleen

Scientific

Universitair Ziekenhuis Gent

研究点 (1)

Loading locations...

相似试验